Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: A pooled analysis of individual patient data from 17 population-based studies from China

The Lancet Oncology

Volumn 11, Issue 12, 2010, Pages 1160-1171

  Zhao, Fang Hui ^a   Lin, Margaret Jane ^b   Chen, Feng ^a   Hu, Shang Ying ^a   Zhang, Rong ^a   Belinson, Jerome L ^c   Sellors, John W ^d   Franceschi, Silvia ^e   Qiao, You Lin ^a   Castle, Philip E ^f  

^a CANCER HOSPITAL   (China)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER SCREENING; CHINA; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FEMALE; GENETIC SCREENING; HEALTH PROGRAM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT REFERRAL; POPULATION RESEARCH; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; CHINA; DNA PROBES, HPV; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 78649635466     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70256-4     Document Type: Article

References (41)

1. Parkin DM, Bray F Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(suppl 3):S3. 11-25.
2. Chapter 2: screening tests. IARC handbooks of cancer prevention: cervix cancer screening 2005, vol 10:59-115. International Agency for Research on Cancer, IARC Press, Lyon.
3. IARC monographs on the evaluation of carcinogenic risks to humans, vol 90: human papillomaviruses 2007, International Agency for Research on Cancer, IARC Press, Lyon.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
5. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
6. Arbyn M, Ronco G, Meijer CJ, Naucler P Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009, 10:935-936.
7. Castle PE, Katki HA Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol 2010, 11:214-215.
8. Yang L, Huangpu XM, Zhang SW, et al. Changes of mortality rate for cervical cancer during 1970's and 1990's periods in China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003, 25:386-390.
9. Shi JF, Qiao YL, Smith JS, et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 2008, 26(suppl 12):M53-M59.
10. Qiao YL Perspective of cervical cancer prevention and control in developing countries and areas. Ai Zheng 2010, 29:1-3.
11. Women's health in rural China. Lancet 2009, 374:358. The Lancet.
12. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936.
13. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001, 83:439-444.
14. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003, 13:819-826.
15. Moy L, Zhao F, Li L, et al. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer 2010, 127:646-656.
16. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
17. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(suppl 3):S3. 78-89.
18. Levin CE, Sellors J, Shi JF, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer 2010, 127:1404-1411.
19. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008, 100:492-501.
20. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
21. Dai M, Bao YP, Li N, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 2006, 95:96-101.
22. Belinson JL, Hu S, Niyazi M, et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. Int J Cancer 2010, 127:1151-1157.
23. Pan Q, Belinson JL, Li L, et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study. Acta Cytol 2003, 47:45-50.
24. Belinson JL, Pretorius RG, Zhang WH, et al. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001, 98:441-444.
25. Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 2006, 10:5-9.
26. Belinson JL, Pan QJ, Biscotti C, et al. Primary screening with liquid-based cytology in an unscreened population in rural China, with an emphasis on reprocessing unsatisfactory samples. Acta Cytol 2002, 46:470-474.
27. Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004, 191:430-434.
28. Cagle AJ, Hu SY, Sellors JW, et al. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid. Int J Cancer 2010, 126:156-161.
29. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
30. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
31. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002, 288:1749-1757.
32. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
33. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101:1612-1623.
34. Li LK, Dai M, Clifford GM, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study. Br J Cancer 2006, 95:1593-1597.
35. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158:486-494.
36. Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010, 48:554-558.
37. Rijkaart DC, Coupe VM, van Kemenade FJ, et al. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010, 103:939-946.
38. Castle PE, Schiffman M, Wheeler CM, Solomon D Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113:18-25.
39. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008, 123:153-160.
40. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer 2009, 125:2489-2496.
41. Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004, 103:304-309.